Expanding Redx Inks Cancer Alliance with Pharmascience
LONDON – Redx Pharma Ltd. has unveiled a shift in strategy away from a sole focus on internally generated compounds, with the in-licensing of an early stage oncology program from Canadian biotech Pharmascience Inc. At the same time Redx announced it has put in place funding for a diversification into anti-infectives and is opening a new unit on the site of AstraZeneca plc's largest R&D facility at Alderley Park, Cheshire, UK.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter